As previously reported, Scotiabank analyst George Farmer initiated coverage of Viking Therapeutics (VKTX) with an Outperform rating and $102 ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Viking Therapeutics stock plunged early Thursday on an earnings report that included mostly incremental updates for its ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Viking Therapeutics VKTX is set to report fourth ... which includes three candidates — VK2735 (for obesity), VK2809 (for non-alcoholic steatohepatitis [NASH]) and VK0214 (for X-linked ...

HC Wainwright reiterated a “buy” rating and set a $102.00 target price on shares of Viking Therapeutics in a report on Friday, January 17th. B. Riley started coverage on shares of Viking ...

Viking Therapeutics Inc.’s stock jumped 3% Tuesday, after a bullish note from Oppenheimer highlighted the company’s promising obesity-drug program and its potential appeal to a deep-pocketed ...

It has been a little more than two months since my last Viking Therapeutics ... Furthermore, I have only mentioned VK2735’s potential… we haven’t added in the company’s VK2809 program ...

Viking Therapeutics(NASDAQ ... Viking focuses on GIP/GLP-1 receptor agonists and has a candidate, VK2735, in late-stage clinical trials. As an injectable (like the Novo Nordisk and Lilly ...

The real Holy Grail is a weight-loss-in-a-pill formulation, which has investors very interested in Viking Therapeutics‘ (NASDAQ:VKTX) VK2735, which is showing better efficacy than Novo Nordisk ...

The latest trading session saw Viking Therapeutics, Inc. (VKTX) ending at $32.87, denoting a +0.67% adjustment from its last day's close. The stock's performance was behind the S&P 500's daily gain of ...